Epidiolex 100 mg/mL Oral Solution
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Dravet Syndrome (DS)
Conditions
Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
Trial Timeline
Jun 1, 2026 → Jun 1, 2029
NCT ID
NCT06924827About Epidiolex 100 mg/mL Oral Solution
Epidiolex 100 mg/mL Oral Solution is a approved stage product being developed by Jazz Pharmaceuticals for Dravet Syndrome (DS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06924827. Target conditions include Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS).
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06924827 | Approved | Recruiting |
| NCT05485831 | Pre-clinical | Recruiting |
| NCT04721691 | Phase 1 | Completed |
Competing Products
15 competing products in Dravet Syndrome (DS)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| ZX008 0.2 to 0.8 mg/kg/day + Cannabidiol | UCB | Phase 1 | 30 |
| fenfluramine | UCB | Approved | 82 |
| Fenfluramine Hydrochloride | UCB | Pre-clinical | 20 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 74 |
| ZX008 (Fenfluramine Hydrochloride) | UCB | Phase 3 | 74 |
| fenfluramine | UCB | Phase 3 | 74 |
| ZX008 (Fenfluramine Hydrochloride) + Matching Placebo | UCB | Phase 3 | 74 |
| Clobazam | Lundbeck | Phase 3 | 74 |
| Clobazam + Placebo | Lundbeck | Phase 3 | 74 |
| zorevunersen | Stoke Therapeutics | Phase 3 | 72 |
| STK-001 - Single Ascending Doses + STK-001 - Multiple Ascending Doses | Stoke Therapeutics | Phase 1/2 | 36 |
| zorevunersen (STK-001) | Stoke Therapeutics | Phase 2 | 47 |
| Clemizole HCl + Placebo | Harmony Biosciences | Phase 3 | 72 |